期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 571, 期 1, 页码 39-43出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2007.06.004
关键词
cannabinoid receptor; methamphetamine; AM251; reinstatement; self-administration; (Rat)
资金
- NIDA NIH HHS [K02 DA000211, R01 DA004195, DA04195, DA17918, K02 DA000211-11, R01 DA004195-13, K05 DA017918] Funding Source: Medline
Cannabinoid CB1 receptor antagonists can decrease methamphetamine self-administration. This study examined whether the CB1 receptor antagonist AM251 [N-(piperidin-1-yl)-5-(4-indophonyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide] modifies reinstatement in rats that previously self-administered methamphetamine. Rats (n = 10) self-administered methamphetamine (0.1 mg/kg/infusion) under a fixed ratio 2 schedule. Non-contingent methamphetamine (0.01-1.78 mg/kg, i.v.) yielded responding for saline (reinstatement) that was similar to responding for self-administered methamphetamine. AM251 (0.032-0.32, i.v.) did not affect methamphetamine-induced reinstatement but significantly attenuated Delta(9)-tetrahydrocannabinol (2.0 mg/kg, i.p.)-induced hypothermia. These data fail to support a role for endogenous cannabinoids or cannabinoid CB1 receptors in reinstatement and, therefore, relapse to stimulant abuse. (c) 2007 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据